Hiteshi K.C. Chauhan: Oral Anticoagulant Reversal in Major Bleeding and Urgent Surgery
Hiteshi K.C. Chauhan, Consultant, Department of Cardiology at Fortis Healthcare, shared a post on LinkedIn about a recent article by Bianca Rocca et al., published in NEJM, adding:
“Anticoagulation Reversal: Right Treatment. Right Patient. Right Time.
As anticoagulant use continues to increase across cardiovascular practice, timely and appropriate reversal is becoming increasingly important.
Effective reversal strategies can reduce bleeding-related morbidity, facilitate urgent interventions, and help balance the competing risks of haemorrhage and thrombosis.
Familiarity with these pathways is therefore essential for clinicians managing acutely unwell patients.
Management of oral anticoagulant reversal remains a common and high-stakes clinical challenge, particularly in patients presenting with major bleeding or requiring urgent surgery.
This practical framework highlights the key considerations for reversal across different anticoagulant classes:
- Vitamin K antagonists: reversal guided by bleeding severity, INR, and procedural urgency, using vitamin K and/or 4-factor PCC.
- Factor Xa inhibitors: decision-making centred on the ‘4 Ts’ – type of bleeding, timing of last dose, thrombotic risk, and anticipated need for procedures. Treatment options include specific reversal agents (andexanet alfa) or 4-factor PCC.
- Dabigatran: reversal guided by the ‘3 Rs’ – risk (bleeding severity), residual drug activity, and renal function, with idarucizumab as the specific antidote.
What protocols does your institution follow for anticoagulant reversal in major bleeding or emergency procedures?”
Title: Antidotes for Anticoagulation Reversal
Authors: Bianca Rocca, Hugo ten Cat
Stay updated with Hemostasis Today.
-
Jun 16, 2026, 14:50Abdulrahman Nasiri: Honored to Share our Research Contributions at the EHA 2026
-
Jun 16, 2026, 14:49An Overview of Bernard–Soulier Syndrome – ICHCC
-
Jun 16, 2026, 14:47David Walcott: Blood Supply as Essential Healthcare Infrastructure
-
Jun 16, 2026, 14:36Catalin Bobirca: EHA 2026 Showcases the Future of Hemoglobinopathies Care
-
Jun 16, 2026, 14:30Jeffrey Kallberg: Education and Advocacy at the Texas Bleeding Disorders Conference
-
Jun 16, 2026, 14:23Alfadil Haroon: Bleeding Outcomes in Congenital Versus Acquired FXIII Deficiency
-
Jun 16, 2026, 14:20Matthew James: Anticoagulation Errors – 5 Prescribing Red Flags That Lead to Bleeding
-
Jun 16, 2026, 14:13Miguel Crato: Pleased to Share the Farewell Speech Closing My Chapter as President of the EHC
-
Jun 16, 2026, 14:09Abdul Mannan: Antiphospholipid Syndrome in Thrombotic Storm Mode